Acadia Pharma (ACAD) Misses Q4 EPS by 3c

Acadia Pharma (NASDAQ: ACAD) reported Q4 EPS of ($0.27), $0.03 worse than the analyst estimate of ($0.24). Revenue for the quarter came in at $130.76 million versus the consensus estimate of $135.6 million.

GUIANCE:

2022 Financial Guidance

• NUPLAZID net sales guidance in Parkinson’s disease psychosis is $510 to $560 million.
• GAAP R&D guidance is $355 to $375 million and includes approximately $25 million of stock-based compensation expense.
• GAAP SG&A guidance is $360 to $380 million and includes approximately $45 million of stock-based compensation expense.

For earnings history and earnings-related data on Acadia Pharma (ACAD) click here.

You May Also Be Interested In

• BJ's Wholesale Club (BJ) Tops Q2 EPS by 19c, Beats on Revenue; Offers FY27 EPS Guidance
• Deere & Co. (DE) Tops Q3 EPS by 41c, raises guidance
• Opera Limited (OPRA) Misses Q2 EPS by 1c ; Offers Guidance